Bright Minds Biosciences Inc. (NASDAQ: DRUG) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT BRIGHT MINDS BIOSCIENCES INC.

Bright Minds Biosciences Inc. (NASDAQ: DRUG)
Listen to this Section


$69.27
-5.2300 ( -7.02% ) 498.1K

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Clinical Trial Pipeline Stages


Drug Name Stage
BMB-101DetailsEpilepsy, Developmental and Epileptic Encephalopathy Phase 2

Market Data


Open $69.27
Previous Close $74.50
Volume 498.1K
Market Cap $730.21M
Day Range $69.20 - $74.67
52 Week Range $23.18 - $123.75
Shares Outstanding 9.81M
Change % -7.02%
Net Change ▼ -5.2300
Insider Ownership 0.04%
Exchange NASDAQ
SectorHealthcare
IndustryPharmaceuticals and Biotechnology
IPO Year2021
CountryCanada

Insider Ownership Transactions

Total Amount Purchased: 422,428.00

Date Type Amount Purchased Purchaser
2024-11-06 Buy 184331.00 Cormorant Asset Management, LP
2024-10-17 Buy 238097.00 Cormorant Asset Management, LP

SEC Filings


Form Type Description Pages Date
schedule Other 2 Nov 14, 2025
schedule Other 2 Nov 13, 2025
schedule Other 1 Nov 12, 2025
6-k Form 6-K 3 Nov 07, 2025
6-k Form 6-K 2 Nov 07, 2025
6-k Form 6-K 2 Sep 05, 2025
6-k Form 6-K 8 Aug 15, 2025
6-k Form 6-K 8 Aug 11, 2025

Latest News


× Before browsing our site, please accept our cookies policy